相关实验视频
Updated: Jun 24, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在初级保健中管理SGLT2抑制剂的患者
Javed Butler1, John E Anderson2
1Baylor Scott and White Research Institute, Dallas, Texas, USA; Baylor Scott and White Health, Dallas, Texas, USA; University of Mississippi Medical Center, Jackson, Mississipe, USA.
JACC. Heart failure
|June 5, 2024
概括
本视频解释了如何在初级保健机构管理服用-葡萄糖共运输体2 (SGLT2) 抑制剂的患者. 学习有效的患者护理和治疗优化的基本策略.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 主要护理医学 医疗保健
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂越来越多地用于心血管和的益处.
- 初级保健医生需要指导管理开始SGLT2抑制剂治疗的患者.
研究的目的:
- 为在初级保健中提供关于SGLT2抑制剂患者管理的实用见解.
- 要突出启动和监测SGLT2抑制剂治疗的关键考虑因素.
主要方法:
- 专家讨论和临床案例示例.
- 专注于在初级保健机构的现实应用.
主要成果:
- 讨论包括患者选择,剂量定位和潜在的副作用.
- 强调将SGLT2抑制剂纳入现有治疗方案.
结论:
- 在初级保健中有效管理SGLT2抑制剂是可以通过适当的知识实现的.
- 优化SGLT2抑制剂的使用可以改善患者的治疗结果.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
Diabetes: Management and Pharmacotherapy
260
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
260
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189
Secondary Active Transport
119.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.3K
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152

